Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistFWD Care, Inc. was cited for unlawfully selling unapproved and misbranded compounded drugs—specifically semaglutide and tirzepatide products—over the internet to U.S. consumers. The company made false or misleading claims that its compounded products were "the same active ingredient" as FDA-approved drugs like Wegovy, Ozempic, Zepbound, and Mounjaro, which violated sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. These claims improperly implied the compounded products were equivalent to approved medications when compounded drugs are not FDA-approved, resulting in misbranded products introduced into interstate commerce in violation of section 301(a) of the FDCA.